| Bioactivity | TMU 35435 is a histone deacetylase (HDAC) inhibitor. TMU-35435 inhibits the NHEJ pathway through ubiquitination of DNA-dependent protein kinase catalytic subunit (DNA-PKcs). In addition, TMU 35435 enhances radiosensitivity by inducing misfolded protein aggregation and autophagy in TNBC[1][2]. |
| CAS | 2231800-32-9 |
| Formula | C22H25N3O3 |
| Molar Mass | 379.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Huiwen Chiu, et al. "A new histone deacetylase inhibitor enhances radiation sensitivity through the induction of misfolded protein aggregation and autophagy in triple-negative breast cancer." Cancers 11.11 (2019): 1703. [2]. Yuanhua Wu, et al. "A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer." Cancer letters 400 (2017): 79-88. |
TMU 35435
CAS: 2231800-32-9 F: C22H25N3O3 W: 379.45
TMU 35435 is a histone deacetylase (HDAC) inhibitor. TMU-35435 inhibits the NHEJ pathway through ubiquitination of DNA-d
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.